GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hisamitsu Pharmaceutical Co Inc (FRA:HPX) » Definitions » Long-Term Capital Lease Obligation

Hisamitsu Pharmaceutical Co (FRA:HPX) Long-Term Capital Lease Obligation : €0.0 Mil (As of Aug. 2024)


View and export this data going back to . Start your Free Trial

What is Hisamitsu Pharmaceutical Co Long-Term Capital Lease Obligation?

Hisamitsu Pharmaceutical Co's Long-Term Capital Lease Obligation for the quarter that ended in Aug. 2024 was €0.0 Mil.

Hisamitsu Pharmaceutical Co's quarterly Long-Term Capital Lease Obligation declined from Feb. 2024 (€3.7 Mil) to May. 2024 (€0.0 Mil) but then stayed the same from May. 2024 (€0.0 Mil) to Aug. 2024 (€0.0 Mil).

Hisamitsu Pharmaceutical Co's annual Long-Term Capital Lease Obligation declined from Feb. 2022 (€6.6 Mil) to Feb. 2023 (€5.3 Mil) and declined from Feb. 2023 (€5.3 Mil) to Feb. 2024 (€3.7 Mil).

Hisamitsu Pharmaceutical Co Long-Term Capital Lease Obligation Historical Data

The historical data trend for Hisamitsu Pharmaceutical Co's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hisamitsu Pharmaceutical Co Long-Term Capital Lease Obligation Chart

Hisamitsu Pharmaceutical Co Annual Data
Trend Feb15 Feb16 Feb17 Feb18 Feb19 Feb20 Feb21 Feb22 Feb23 Feb24
Long-Term Capital Lease Obligation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.08 0.74 6.64 5.27 3.74

Hisamitsu Pharmaceutical Co Quarterly Data
Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24
Long-Term Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 3.74 - -

Hisamitsu Pharmaceutical Co  (FRA:HPX) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Hisamitsu Pharmaceutical Co Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Hisamitsu Pharmaceutical Co's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Hisamitsu Pharmaceutical Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hisamitsu Pharmaceutical Co Inc (FRA:HPX) » Definitions » Long-Term Capital Lease Obligation
Comparable Companies
TSE:4516 TSE:4581 TSE:4887 TSE:4540 TSE:4506 TSE:4547 TSE:4553 TSE:4521 TSE:4534 TSE:4551 ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
HTSUY:USA 4530:Japan
Address
408 Tashiro Daikan-machi, Tosu, Saga, JPN, 841-0017
Website
http://www.hisamitsu.co.jp
Hisamitsu Pharmaceutical Co Inc is a major pharmaceutical products manufacturer in Japan. The company collaborates with its subsidiaries and associates in operating its business across two segments, The Medical and Related Product segment and the Others segment. The Medical segment represents the company's foremost revenue generating operations. It markets drugs under the Salanpas, Salonsip, Lifecella, Mohrus and Keplat brands, which mainly serve topical medication needs with pain relief creams, gels, sprays, lotions and ointments. The Others segment refers to its miscellaneous businesses such as cable television broadcasting, internet connection, packing materials and insurance. Apart from its primary market in Japan, Hisamitsu has a reach across other regions like North America.